gene therapy
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
Evotec Announces Restructuring Plan Amid Research Spending Slowdown
Evotec, layoffs, restructuring, research spending slowdown, gene therapy, biopharma
Precigen Restructures, Reduces CAR-T Efforts Amid Job Cuts
Precigen, CAR-T, restructuring, job cuts, UltraCAR-T, gene therapy, AdenoVerse, PRGN-2012
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
Gene Therapy Pioneer Jim Wilson Departs UPenn to Launch Two New Biotech Companies
Jim Wilson, UPenn, gene therapy, biotech companies, GEMMA Biotherapeutics, Franklin Biolabs
Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs
uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials
Sanofi Sues Sarepta Over US Patents for Gene Therapy Treatments
Sanofi, Sarepta, Gene Therapy, Patents, Elevidys, Duchenne Muscular Dystrophy
Pfizer Lays Off 210 Workers in North Carolina Following Discontinuation of Duchenne Gene Therapy
Pfizer, Layoffs, North Carolina, Duchenne Gene Therapy, Muscular Dystrophy, Gene Therapy Program
Pfizer and Sangamo’s Gene Therapy Shows Superiority Over Prophylaxis in Hemophilia A Study
Pfizer, Sangamo, gene therapy, hemophilia A, prophylaxis, giroctocogene fitelparvovec, bleeding rate, Factor VIII